Fourth Quarter and Year End 2011 Financial Results Conference Call
February 27, 2012
Fourth Quarter and Year Results Conference Call End 2011 Financial - - PDF document
Fourth Quarter and Year Results Conference Call End 2011 Financial February 27, 2012 Forward-looking Statements Forward-looking Statements Certain statements made in this presentation may constitute forward-looking statements, including, but
February 27, 2012
1
Forward-looking Statements Certain statements made in this presentation may constitute forward-looking statements, including, but not limited to, statements regarding guidance with respect to integration-related activities, product candidates in development, timing of product launches and expected benefits from acquisitions by the Company. Forward-looking statements may be identified by the use of the words “anticipates,” “expects,” “intends,” “plans,” “could,” “should,” “would,” “may,” “will,” “believes,” “estimates,” “potential,” or “continue” and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward- looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the Company's most recent annual or quarterly report filed with the Securities and Exchange Commission ("SEC") and other risks and uncertainties detailed from time to time in the Company's filings with the SEC and the Canadian Securities Administrators ("CSA"), which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. The Company undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date
Non-GAAP Information To supplement the financial measures prepared in accordance with generally accepted accounting principles (GAAP), the Company uses non-GAAP financial measures that exclude certain items, such as amortization of inventory step-up, stock-based compensation step-up, restructuring and acquisition-related costsTBD, acquired in-process research and development ("IPR&D"), legal settlements, amortization and other non-cash charges, amortization of deferred financing costs, debt discounts and ASC 470-20 (FSP APB 14-1) interest, loss on extinguishment of debt, and (gain) loss on investments, net, and adjusts tax expense to cash taxes. Management uses non-GAAP financial measures internally for strategic decision making, forecasting future results and evaluating current performance. By disclosing non-GAAP financial measures, management intends to provide investors with a meaningful, consistent comparison of the company’s core operating results and trends for the periods presented. Non-GAAP financial measures are not prepared in accordance with GAAP; therefore, the information is not necessarily comparable to other companies and should be considered as a supplement to, not a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP.
2
3
Total Revenue = $688 million
34% revenue growth over 2010
Product sales = $654 million
34% product sales growth over 2010 10% organic product sales growth over 2010
Cash EPS = $0.94
88% Cash EPS growth over 2010
Adjusted Cash Flow from Operations = $253 million
22% adjusted cash flow from operations growth over 2010 Excluding changes in working capital - adjusted cash flow from
4
$0.62 $0.73 $0.54 $0.57 $0.94 $0.66 1st Qtr 2nd Qtr 3rd Qtr 4th Qtr
Reported Cash EPS Adjusted Cash EPS
Total 2011 Revenue = $2.46 Billion Total Cash EPS = $2.93
* Adjusted for Cloderm divestiture (Q1 2011) and Trobalt milestone (Q2 2011)
$529 $569 $565 $609 $601 $688 1st Qtr 2nd Qtr 3rd Qtr 4th Qtr
Reported Product Sales Adjusted Product Sales
5
39%
14% 3%
7%
10%
Organic Growth
32%
13% 13% 10%
9%
Organic Growth
Fourth Quarter 2011 Full Year 2011
Branded Generics - LA Canada/ Australia U.S Neurology & Other U.S Dermatology
Total Organic Growth
Branded Generics - EU
6
$253 $208 $260 $204
1st Qtr 2nd Qtr* 3rd Qtr 4th Qtr Excluded Items:
Total 2011 Adjusted Cash Flow from Operations = $925 Million
* Includes $40 M Milestone payment from GSK
Related Costs
7
Revenue $2.1-$2.3 billion Organic Growth ~8% Cash EPS $2.25 - $2.50 >$800 million in Adjusted
Cash Flow from Operations
Revenue $2.46 billion Organic Growth 9% Cash EPS $2.93 $925 million in
Adjusted Cash Flow from Operations
8
Completed in Q4 2011
Ortho Dermik Afexa iNova
Announced YTD 2012
Probiotica EyeTech
9
Run rate expected by mid-year Run Rate YTD
$200 million $135 million
11
Completed Ongoing
Sales and Marketing Sales force optimization/restructuring Marketing combination A&P rationalization
Program rationalization People reduction
Supply agreements Long-term tech transfers
Order to cash
Commercial Manufacturing plant
12
2011 vs. 2010 Volume Growth
Source: Wolters Kluwer Health; IRI Scan data; Retailer data
54% 25% 29% 27%
0% 10% 20% 30% 40% 50% 60% 70% Acanya Atralin Zovirax* CeraVe**
* Zovirax volume in TRx grams; **Cerave Scan Volume growth
13
10,000 20,000 30,000 40,000 50,000 60,000 70,000 80,000 90,000 100,000 Q1 2009 Q2 2009 Q3 2009 Q4 2009 Q1 2010 Q2 2010 Q3 2010 Q4 2010 Q1 2011 Q2 2011 Q3 2011 Q4 2011 Acanya Atralin
Source: Wolters-Kluwer; Data for all prescribers
Revamping of Co-Pay Cards
14
0% FY 2011 Q4 2011 Jan-12
Elidel YOY TRx Growth All Prescribers
Source: Wolters Kluwer Health
Elidel YOY TRx Growth Dermatologists
9%
0% 5% 10% 15% FY 2011 Q4 2011 Jan-12
15
Source: Wolters-Kluwer; Data for all prescribers
0.0% 5.0% 10.0% 15.0% 20.0% 25.0% 30.0% 35.0% 40.0% 45.0% 50.0%
Q1 2010 Q2 2010 Q3 2010 Q4 2010 Q1 2011 Q2 2011 Q3 2011 Q4 2011
TRx Grams vs. Prior year % Growth
12% 43% 47%
16
70%
Hydrating Cleanser Lotion Cream Facial PM Lotion AM Foaming Cleanser
+26% +27% +34% +101% +361% +332%
Original SKUs Newer SKUs
Proportion of Business 30%
Source: IRI Scan data; Retailer data
17
New Products Lifecycle Management Generics
Onychomycosis (IDP-108) Psoriasis (IDP-118) Acne (IDP-107 / MC5) Acanya RAM Sculptra
Undisclosed
19
* Excludes fair value step-up adjustment to inventory and other non-GAAP items
** Q410 & Q411 includes the impact of working capital changes of $22 million and $62 million respectively
Q4 2010 Q1 2011 Q2 2011 Q3 2011 Q4 2011 2011 Product Sales $489m $500m $530m $570m $654m $2,255m Total Revenue $515m $565m $609m $601m $688m $2,463m Cost of Goods Sold %* 31% 24% 29% 28% 25% 27% SG&A % 22% 21% 22% 21% 21% 21% R&D Expense $18m $14m $18m $18m $17m $66m Operating Margin (excluding amortization) 45% 50% 53% 50% 57% 51% Cash EPS $0.50 $0.62 $0.73 $0.66 $0.94 $2.93 Adjusted Cash Flow from Operations $187m** $204m $260m $208m $253m** $925m
20
Q4 10 Q4 11 FY 11 FY 12 e U.S. Dermatology 103.9 174.2 568.3 900-925 U.S. Neurology & Other 213.0 202.8 829.3 675-750 Canada/Australia 80.5 101.3 340.1 550-625 Branded Generics Latin America 69.0 65.8 254.9 >275 Branded Generics Europe 48.3 144.4 470.9 >625 South East Asia/South Africa N/A N/A N/A ~100 Emerging Markets N/A N/A N/A >1.0 B Total Revenue 514.6 $ 688.5 $ 2,463.5 $ $3.1 - $3.4 b
21
4Q Price 4Q Volume 4Q Total 2011 Price 39%
8% 2% 1% 0%
14% 3% % 2011 Volume 33%
11% 12% 10% U.S. Neuro 8%
Branded Generics – Europe 0% 7% 10% Canada/ Australia 2% 2011 Total U.S. Derm
45% 12% 32% Branded Generics
2% 1% 13% 13%
22
Q4 10 Q4 11 FY 11
U.S. Neuro & Other 24% 17% 17% U.S. Dermatology 35% 11% 15% Canada/Australia 28% 23% 28% Branded Generics - Europe 38% 47% 48% Branded Generics - Latin America 42% 37% 39%
Total 31% 25% 27%
23
$166 $59 $2,876 $2,653 $68 $164 $394 $925 $639
Current cash (2/24) position ~$570 m + $275 m undrawn revolver
Cash December 2010 Securities Repurchases Acquisitions Cap Ex Restructuring/ Integration/ Legal Settlements Other* Cash December 2011 Issuance LT Debt Adjusted CashFlow from Operations
* Includes payment of withholding tax upon vesting of share based awards, one-time working capital adjustments, proceeds from the
exercise of stock options and other miscellaneous cash outflows
24
Currency 2010 vs 2011 2012 YTD
Poland Serbia Hungary Russia Australia Canada Mexico Brazil South Africa
10% 1% 9% 9% 4% 2% 7% 9% 6%
25
New Segment Reporting
U.S. Derm U.S. Neuro & Other Canada/Australia Emerging Markets
Number of Shares Outstanding
317 million diluted shares as of December 31, 2011
Decreased by 12 million shares from December 31, 2010
Strong Liquidity
Current cash position of ~$570 million $275 million undrawn revolver
Recent Financing
$600 million senior secured Tranche B Term Loan
LIBOR + 2.75% with 1% LIBOR floor
February 27, 2012